Participants age 18 Years and older with Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-14
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-14
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Adults with advanced, heavily pretreated endometrial cancer (n=27 in this cohort), enrolled in the gynecologic expansion cohort of a first-in-human, phase 1 trial. A separate cohort of the SAME trial (n=24) enrolled patients with platinum-resistant ovarian cancer; both cohorts' results are reported together here since they come from the same combination and the same trial, though this record's cancer_type taxonomy tag reflects the endometrial cohort specifically.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Adults with recurrent, platinum-resistant ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing folate receptor alpha (FRα), who received 1-3 prior lines of therapy, enrolled in the dose-optimization portion of a phase 2/3 trial that has since been terminated before its planned randomized phase 3 portion began (see correction_note). Efficacy figures here are from the 25-patient cohort receiving the dosing regimen originally selected for further study.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Adults enrolled across three cohorts of a first-in-human phase 1 trial: (1a) triple-negative breast cancer (TNBC) survivors who completed treatment within the prior three years and remain at high recurrence risk; (1b) cancer-free carriers of breast-cancer-associated genetic mutations who elected preventive mastectomy; and (1c) early-stage TNBC patients who received pre-operative chemoimmunotherapy and were subsequently vaccinated in combination with pembrolizumab.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Adults with high-risk, fully surgically resected clear cell renal cell carcinoma (stage III or IV, no remaining visible cancer after surgery), given a personalized neoantigen vaccine with or without ipilimumab in the adjuvant (post-surgery, preventive) setting, in a phase 1, first-in-human trial.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Adults with 1 to 3 painful bone metastases in the thorax (excluding the spine), regardless of the primary cancer's site of origin, enrolled in the single-arm, FDA investigational-device-exemption-approved FAST-02 feasibility trial.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): protocol for a prospective study of a novel radiotherapy approach (Radiation Oncology). DOI 10.1186/s13014-024-02419-4.
Adults with resectable, stage I-III right-sided colon cancer, enrolled in the prospective, open-label, single-arm, phase 2 ROBOCOLO trial at two institutions in Japan.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Surgical outcomes of a prospective, phase 2 trial of robotic surgery for resectable right-sided colon cancer (the ROBOCOLO trial) (Annals of Gastroenterological Surgery). DOI 10.1002/ags3.12718.
Adults with unresectable, non-metastatic, intermediate-stage hepatocellular carcinoma (liver cancer) without extrahepatic spread or vascular invasion, randomized to transarterial chemoembolization (TACE) plus lenvatinib plus pembrolizumab, or TACE plus dual placebo, at 137 sites across 33 countries.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
LEAP-012: transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (The Lancet). DOI 10.1016/S0140-6736(24)02575-3.
Adults with hormone-receptor-positive, HER2-negative locally advanced, inoperable, or metastatic breast cancer previously treated with endocrine therapy and eligible for first-line chemotherapy, randomized 2:1 to sacituzumab govitecan or standard-of-care chemotherapy, in the randomized, open-label, phase 3 ASCENT-07 trial.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.